. 2019 May 11;49(8):3218–3230. doi: 10.1007/s10803-019-04046-5

Table 4.

Caregivers responses after 3 and 13 weeks of double blind treatment

Variable	Group	Adjusted treatment means (SE) [95% CI]	Treatment difference (SE)	95% CI	p-value*
3 weeks
WHO-5	PedPRM	1.53 (0.515) [0.51; 2.55]	1.60 (0.729)	0.16, 3.05	0.030
WHO-5	Placebo	− 0.07 (0.516) [− 1.09; 0.95]	1.60 (0.729)	0.16, 3.05	0.030
PSQI	PedPRM	− 1.09 (0.360) [− 1.80, − 0.38]	− 0.75 (0.510)	− 1.76, 0.26	0.146
PSQI	Placebo	− 0.34 (0.361) [− 1.06, 0.37]	− 0.75 (0.510)	− 1.76, 0.26	0.146
ESS	PedPRM	− 0.84 (0.395) [− 1.62, − 0.06]	− 1.04 (0.561)	− 2.15, 0.07	0.067
ESS	Placebo	0.02 (0.396) [− 0.59, 0.99]	− 1.04 (0.561)	− 2.15, 0.07	0.067
13 weeks
WHO-5	PedPRM	1.43 (0.565) [0.31, 2.55]	2.17 (0.831)	0.53, 3.82	0.010
WHO-5	Placebo	− 0.75 (0.608) [− 1.95, 0.46]	2.17 (0.831)	0.53, 3.82	0.010
PSQI	PedPRM	− 1.11 (0.395) [− 1.89, − 0.32]	− 0.81 (0.582)	− 1.97, 0.34	0.166
PSQI	Placebo	− 0.29 (0.427) [− 1.14, 0.55]	− 0.81 (0.582)	− 1.97, 0.34	0.166
ESS	PedPRM	− 0.74 (0.510) [− 1.76, 0.27]	− 1.29 (0.752)	− 2.78, 0.20	0.089
ESS	Placebo	0.55 (0.552) [− 0.55, 1.64]	− 1.29 (0.752)	− 2.78, 0.20	0.089

*MMRM analysis compared to placebo